Rational Design of Targeted Next-Generation Carriers for Drug and Vaccine Delivery

Annual Review of Biomedical Engineering

Volumn 18, Issue , 2016, Pages 25-49

  Narasimhan, Balaji ^a   Goodman, Jonathan T ^a   Vela Ramirez, Julia E ^a  

^a Iowa State University   (United States)

Author keywords

Brain drug delivery; C type lectin receptors; Cancer; Drug delivery vehicles; Folate receptors; Toll like receptors

Indexed keywords

IMMUNE SYSTEM; PATTERN RECOGNITION; PROTEINS; VACCINES;

BRAIN DRUG DELIVERIES; C-TYPE LECTINS; CANCER; DRUG DELIVERY VEHICLES; FOLATE RECEPTOR; TOLL-LIKE RECEPTORS;

DISEASES;

ANTIBODY; ANTIGEN; DRUG; DRUG CARRIER; FOLATE RECEPTOR; LECTIN RECEPTOR; TOLL LIKE RECEPTOR; VACCINE;

ARTICLE; BACTERIAL INFECTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEUROLOGIC DISEASE; NEXT GENERATION SEQUENCING; NONHUMAN; PROTEIN TARGETING; TARGET CELL; VIRUS INFECTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CHEMISTRY; PROCEDURES;

ANIMALS; DRUG CARRIERS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; VACCINES;

EID: 84978975587     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-082615-030519     Document Type: Article

References (157)

1. Adiseshaiah PP, Hall JB,McNeil SE. 2010. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2:99-112
2. van Vliet SJ, García-Vallejo JJ, van Kooyk Y. 2008. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol. Cell Biol. 86:580-87
3. Zamze S, Martinez-Pomares L, Jones H, Taylor PR, Stillion RJ, et al. 2002. Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the macrophage mannose receptor. J. Biol. Chem. 277:41613-23
4. Fiani ML, Beitz J, Turvy D, Blum JS, Stahl PD. 1998. Regulation of mannose receptor synthesis and turnover in mouse J774 macrophages. J. Leukoc. Biol. 64:85-91
5. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, et al. 2009. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 5:329-40
6. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, et al. 2002. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295:1898-901
7. Gadjeva M, TakahashiK,Thiel S. 2004. Mannan-binding lectin-A soluble pattern recognitionmolecule. Mol. Immunol. 41:113-21
8. Ma YG, Cho MY, Zhao M, Park JW, Matsushita M, et al. 2004. Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement. J. Biol. Chem. 279:25307-12
9. TakahashiM, Iwaki D, Kanno K, IshidaY,Xiong J, et al. 2008. Mannose-binding lectin (MBL)-associated serine protease (MASP) 1 contributes to activation of the lectin complement pathway. J. Immunol. 180:6132-38
10. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7:790-802
11. MahnkeK,Guo M, Lee S, SepulvedaH, Swain SL, et al. 2000. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151:673-84
12. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, et al. 2006. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 18:857-69
13. Gliddon DR,Hope JC, BrookeGP, Howard CJ. 2004. DEC-205 expression on migrating dendritic cells in afferent lymph. Immunology 111:262-72
14. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, et al. 2010. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 116:2277-85
15. Bonifaz L, Bonnyay D, Mahnke K, RiveraM,Nussenzweig MC, Steinman RM. 2002. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196:1627-38
16. Geijtenbeek TB, van Vliet SJ, Engering A, Hart BA, van Kooyk Y. 2004. Self-and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 22:33-54
17. Tabarani G, Reina JJ, Ebel C, Vives C, Lortat-Jacob H, et al. 2006. Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding. FEBS Lett. 580:2402-8
18. Feinberg H, Guo Y, Mitchell DA, Drickamer K, Weis WI. 2005. Extended neck regions stabilize tetramers of the receptors DC-SIGN and DC-SIGNR. J. Biol. Chem. 280:1327-35
19. Azad AK, Torrelles JB, Schlesinger LS. 2008. Mutation in the DC-SIGN cytoplasmic triacidic cluster motif markedly attenuates receptor activity for phagocytosis and endocytosis of mannose-containing ligands by human myeloid cells. J. Leukoc. Biol. 84:1594-603
20. ReidDM,Montoya M, Taylor PR, Borrow P,Gordon S, et al. 2004. Expression of theβ-glucan receptor, dectin-1, on murine leukocytes in situ correlates with its function in pathogen recognition and reveals potential roles in leukocyte interactions. J. Leukoc. Biol. 76:86-94
21. Herre J, Marshall AS, Caron E, Edwards AD, Williams DL, et al. 2004. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 104:4038-45
22. Gringhuis SI, Wevers BA, Kaptein TM, van Capel TM,Theelen B, et al. 2011. SelectiveC-Rel activation via Malt1 controls anti-fungal TH-17 immunity by dectin-1 and dectin-2. PLOS Pathog. 7:e1001259
23. O'Neill LA, Golenbock D, Bowie AG. 2013. The history of Toll-like receptors-redefining innate immunity. Nat. Rev. Immunol. 13:453-60
24. Baumann CL, Aspalter IM, SharifO, Pichlmair A, Blüml S, et al. 2010. CD14 is a coreceptor of Toll-like receptors 7 and 9. J. Exp. Med. 207:2689-701
25. Bernasconi NL, Onai N, Lanzavecchia A. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101:4500-4
26. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. 2004. TLR2 is expressed on activated T cells as a costimulatory receptor. PNAS 101:3029-34
27. NúnezMR, Wong J, Westoll JF, BrooksHJ, O'Neill LA, et al. 2007. A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLOS ONE 2:e788
28. Lebeis SL, Bommarius B, Parkos CA, Sherman MA, Kalman D. 2007. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J. Immunol. 179:566-77
29. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177:7980-89
30. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, et al. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:398-401
31. Alderson MR,McGowan P, Baldridge JR, Probst P. 2006. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12:313-19
32. Ohashi K, Burkart V, Flohe S, Kolb H. 2000. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor 4 complex. J. Immunol. 164:558-61
33. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, et al. 2008. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J. Leukoc. Biol. 83:692-701
34. Yoon SI, KurnasovO,Natarajan V, Hong M, Gudkov AV, et al. 2012. Structural basis ofTLR5-flagellin recognition and signaling. Science 335:859-64
35. Van Maele L, Carnoy C, Cayet D, Songhet P, Dumoutier L, et al. 2010. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3negCD127+ immune cells in spleen and mucosa. J. Immunol. 185:1177-85
36. Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, et al. 2009. Synthetic doublestranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLOS Pathog. 5:e1000373
37. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, et al. 2008. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 320:379-81
38. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, et al. 2011. TLR3-specific doublestranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 186:2422-29
39. Chen K, Xiang Y, Yao X, Liu Y, GongW, et al. 2011. The active contribution of Toll-like receptors to allergic airway inflammation. Int. Immunopharmacol. 11:1391-98
40. IwasakiA,Medzhitov R. 2015. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16:343-53
41. Re F, Strominger JL. 2004. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J. Immunol. 173:7548-55
42. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, et al. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174:1259-68
43. Simchoni N, Cunningham-Rundles C. 2015. TLR7-and TLR9-responsive human B cells share phenotypic and genetic characteristics. J. Immunol. 194:3035-44
44. Franchi L,WarnerN, Viani K,NunezG. 2009. Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev. 227:106-28
45. van Stijn CM, Meyer S, van den Broek M, Bruijns SC, van Kooyk Y, et al. 2010. Schistosoma mansoni worm glycolipids induce an inflammatory phenotype in human dendritic cells by cooperation of TLR4 and DC-SIGN. Mol. Immunol. 47:1544-52
46. Varghese B, Vlashi E, Xia W, Ayala Lopez W, Paulos CM, et al. 2014. Folate receptor-β in activated macrophages: ligand binding and receptor recycling kinetics. Mol. Pharm. 11:3609-16
47. Sabharanjak S,Mayor S. 2004. Folate receptor endocytosis and trafficking. Adv. Drug Deliv. Rev. 56:1099-109
48. Gonen N, Assaraf YG. 2012. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updates 15:183-210
49. Hilgenbrink AR, Low PS. 2005. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94:2135-46
50. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. 2008. The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol. Pharmacol. 74:854-62
51. Wang Y, Zhao R, Goldman ID. 2004. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin. Cancer Res. 10:6256-64
52. Assaraf YG, Leamon CP, Reddy JA. 2014. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist. Updates 17:89-95
53. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, et al. 2014. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin. Cancer Res. 15:448-59
54. Shen J, Hilgenbrink AR, Xia W, Feng Y, Dimitrov DS, et al. 2014. Folate receptor-β constitutes a marker for human proinflammatory monocytes. J. Leukoc. Biol. 96:563-70
55. Lu J, Pang Y, Xie F, Guo H, Li Y, et al. 2011. Synthesis and in vitro/in vivo evaluation of 99mTc-labeled folate conjugates for folate receptor imaging. Nucl. Med. Biol. 38:557-65
56. Muller C, Schibli R. 2011. Folic acid conjugates for nuclear imaging of folate receptor-positive cancer. J. Nucl. Med. 52:1-4
57. Lu Y, Stinnette TW,Westrick E, Klein PJ,GehrkeMA, et al. 2011. Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res. Ther. 13:R56
58. Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, et al. 2013. Structural basis for molecular recognition of folic acid by folate receptors. Nature 500:486-89
59. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, et al. 2013. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. PNAS 110:15180-88
60. van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV. 2013. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 65:1284-98
61. Hesse C, Ginter W, Förg T, Mayer CT, Baru AM, et al. 2013. In vivo targeting of human DC-SIGN drastically enhances CD8+ T-cell-mediated protective immunity. Eur. J. Immunol. 43:2543-53
62. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, et al. 2011. ComparableThelper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. PNAS 108:2384-89
63. Cheong C, Choi JH, Vitale L, He LZ, Trumpfheller C, et al. 2010. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 116:3828-38
64. Hogarth PM, Pietersz GA. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11:311-31
65. Hong Y, Peng Y, Xiao H, Mi M, Munn D, He Y. 2012. Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization. J. Immunol. 188:4819-27
66. Rawool DB, Bitsaktsis C, Li Y, Gosselin DR, Lin Y, et al. 2008. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J. Immunol. 180:5548-57
67. Ejaz A, Ammann CG,Werner R,HuberG,OberhauserV, et al. 2012. Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLOS ONE 7:e45102
68. Castro FV, Tutt AL, White AL, Teeling JL, James S, et al. 2008. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur. J. Immunol. 38:2263-73
69. Daniels TR, Delgado T, Helguera G, Penichet ML. 2006. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121:159-76
70. Normanno N, De Luca A, Bianco C, Strizzi L, MancinoM, et al. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
71. Lin J, Spidel JL, Maddage CJ,RybinskiKA, Kennedy RP, et al. 2013. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol. Ther. 14:1032-38
72. Carter PJ, Senter PD. 2008. Antibody-drug conjugates for cancer therapy. Cancer J. 14:154-69
73. Carter PJ. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6:343-57
74. Reichert JM, Rosensweig CJ, Faden LB,DewitzMC. 2005. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23:1073-78
75. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. 2009. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49:124-32
76. Raïch-Regué D, Naranjo-Gómez M, Grau-López L, Ramo C, Pujol-Borrell R, et al. 2012. Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy. Vaccine 30:378-87
77. Fučíková J, Rožková D, Ulčová H, Budinský V, Sochorová K, et al. 2011. Poly I:C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J. Transl. Med. 9:223
78. Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, et al. 2006. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 119:2428-34
79. Restifo NP, Dudley ME, Rosenberg SA. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12:269-81
80. Rosenberg SA, Yang JC, Sherry RM, Kammula US,HughesMS, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17:4550-57
81. Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, et al. 2008. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28:379-87
82. Adams EW, Ratner DM, Seeberger PH, HacohenN. 2008. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. ChemBioChem 9:294-303
83. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815-24
84. Carrillo-Conde B, Song EH, Chavez-Santoscoy A, Phanse Y, Ramer-Tait AE, et al. 2011. Mannosefunctionalized "pathogen-like" polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol. Pharm. 8:1877-86
85. Singh SK, Stephani J, Schaefer M, Kalay H, García-Vallejo JJ, et al. 2009. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol. Immunol. 47:164-74
86. Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Saeland E, van Kooyk Y. 2011. Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. Int. J. Cancer 128:1371-83
87. KortylewskiM, Swiderski P, Herrmann A, Wang L, Kowolik C, et al. 2009. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27:925-32
88. Higgins SC, Mills KH. 2010. TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants. Curr. Infect. Dis. Rep. 12:4-12
89. Kufer TA, Sansonetti PJ. 2007. Sensing of bacteria: NOD a lonely job. Curr. Opin. Microbiol. 10:62-69
90. Vecchi S, Bufali S, UnoT,WuT, Arcidiacono L, et al. 2014. Conjugation of aTLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. Eur. J. Pharm. Biopharm. 87:310-17
91. Ambrosio AJ, Suzin D, Palmer EL, Penson RT. 2014. Vintafolide (EC145) for the treatment of folatereceptor-α-positive platinum-resistant ovarian cancer. Expert Rev. Clin. Pharmacol. 7:443-50
92. Jia F, Liu X, Li L, Mallapragada S, Narasimhan B, Wang Q. 2013. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control. Release 172:1020-34
93. Phanse Y, Carrillo-Conde BR,Ramer-Tait AE, RoychoudhuryR,PohlNL, et al. 2013. Functionalization of polyanhydride microparticles with di-mannose influences uptake by and intracellular fate within dendritic cells. Acta Biomater. 9:8902-9
94. Chavez-Santoscoy AV, Roychoudhury R, Pohl NL, Wannemuehler MJ, Narasimhan B, Ramer-Tait AE. 2012. Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using "pathogen-like" amphiphilic polyanhydride nanoparticles. Biomaterials 33:4762-72
95. Goodman JT, Vela Ramirez JE, Boggiatto PM, Roychoudhury R, Pohl NL, et al. 2014. Nanoparticle chemistry and functionalization differentially regulates dendritic cell-nanoparticle interactions and triggers dendritic cell maturation. Part. Part. Syst. Charact. 31:11
96. Vela-Ramirez JE, Goodman JT, Boggiatto PM, Roychoudhury R, Pohl NL, et al. 2014. Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles. AAPS J. 17:256-67
97. Tamayo I, Irache JM, Mansilla C, Ochoa-Repáraz J, Lasarte JJ, Gamazo C. 2010. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin. Vaccine Immunol. 17:1356-62
98. Raghuwanshi D,Mishra V, Das D, Kaur K, SureshMR. 2012. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol. Pharm. 9:946-56
99. Demento SL, Bonafe N, Cui W, Kaech SM, Caplan MJ, et al. 2010. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J. Immunol. 185:2989-97
100. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. 2005. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202:1715-24
101. Fahmy TM, Samstein RM, Harness CC, Saltzman MW. 2005. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26:5727-36
102. de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, et al. 2013. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. PNAS 110:19902-7
103. Pavot V, Rochereau N, Primard C, Genin C, Perouzel E, et al. 2013. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J. Control. Release 167:60-67
104. Jena PK, Singh S, Prajapati B, Nareshkumar G, Mehta T, Seshadri S. 2014. Impact of targeted specific antibiotic delivery for gut microbiota modulation on high-fructose-fed rats. Appl. Biochem. Biotechnol. 172:3810-26
105. Xiong MH, Li YJ, Bao Y, Yang XZ, Hu B, Wang J. 2012. Bacteria-responsive multifunctional nanogel for targeted antibiotic delivery. Adv. Mater. 24:6175-80
106. Zhang L, Pornpattananangku D, Hu CM, Huang CM. 2010. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 17:585-94
107. Toti US, Guru BR, Hali M, McPharlin CM,Wykes SM, et al. 2011. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 32:6606-13
108. Montes-Worboys A, Brown S, Regev D, Bellew BF, Mohammed KA, et al. 2010. Targeted delivery of amikacin into granuloma. Am. J. Respir. Crit. Care Med. 182:1546-53
109. Skountzou I, del Pilar Martin,Wang B, Ye L, KoutsonanosD, et al. 2010. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28:4103-12
110. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, et al. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145-52
111. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, et al. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268-74
112. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, et al. 2010. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLOS ONE 5:e13677
113. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, et al. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79:2910-19
114. Urban P, Valle-Delgado JJ, Mauro N, Marques J, Manfredi A, et al. 2014. Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. J. Control. Release 177:84-95
115. Movellan J, Urban P, Moles E, de la Fuente JM, Sierra T, et al. 2014. Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs. Biomaterials 35:7940-50
116. Marques J, Moles E, Urban P, Prohens R, Busquets MA, et al. 2014. Application of heparin as a dual agent with antimalarial and liposome targeting activities toward Plasmodium-infected red blood cells. Nanomedicine 10:1719-28
117. Rosenholm J, Sahlgren C, Lindén M. 2010. Cancer-cell targeting and cell-specific delivery by mesoporous silica nanoparticles. J. Mater. Chem. 20:2707-13
118. Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56:1649-59
119. Danhier F, Feron O, Préat V. 2010. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148:135-46
120. Chan JM, Rhee JW, Drum CL, Bronson RT, Golomb G, et al. 2011. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. PNAS 108:19347-52
121. BhojaniMS, Van Dort M, Rehemtulla A, Ross BD. 2010. Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol. Pharm. 7:1921-29
122. Guo XX, He W, Zhang XJ, Hu XM. 2013. Cytotoxicity of cationic liposomes coated by N-trimethyl chitosan and their in vivo tumor angiogenesis targeting containing doxorubicin. J. Appl. Polym. Sci. 128:21-27
123. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54:631-51
124. Na JH, Koo H, Lee S, Min KH, Park K, et al. 2011. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials 32:5252-61
125. Gao J, Chen K, Xie R, Xie J, Lee S, et al. 2010. Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging. Small 6:256-61
126. Wang F, Zhang D, Zhang Q, Chen Y, Zheng D, et al. 2011. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multidrug resistance. Biomaterials 32:9444-56
127. Suzawa T, Nagamura S, Saito H, Ohta S, Hanai N, et al. 2002. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J. Control. Release 79:229-42
128. Caldorera-Moore ME, Liechty WB, Peppas NA. 2011. Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc. Chem. Res. 44:1061-70
129. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-7
130. Chen QR, Zhang L, Gasper W, Mixson AJ. 2001. Targeting tumor angiogenesis with gene therapy. Mol. Genet. Metabol. 74:120-27
131. Teicher BA. 2000. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist. Updates 3:67-73
132. PardridgeWM. 2005. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14
133. Alley SC, Okeley NM, Senter PD. 2010. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14:529-37
134. Zhao X, Li H, Lee RJ. 2008. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 5:309-19
135. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, et al. 2006. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317:1246-53
136. Bansal A, Kapoor DN, Kapil R, Chhabra N, Dhawan S. 2011. Design and development of paclitaxelloaded bovine serum albumin nanoparticles for brain targeting. Acta Pharm. 61:141-56
137. Wong HL,Wu XY, Bendayan R. 2012. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 64:686-700
138. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. 2011. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J. Control. Release 154:103-7
139. Wohlfart S, Gelperina S, Kreuter J. 2012. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release 161:264-73
140. Mallapragada SK, Brenza TM, McMillan JM, Narasimhan B, Sakaguchi DS, et al. 2015. Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines. Nanomedicine 11:715-29
141. Puligujja P, McMillan J, Kendrick L, Li T, Balkundi S, et al. 2013. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine 9:1263-73
142. Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, et al. 2012. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int. J. Nanomed. 7:2373-88
143. Wu D, PardridgeWM. 1998. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Drug Metabol. Dispos. 26:937-39
144. Wong HL,Wu XY, Bendayan R. 2012. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 64:686-700
145. Bechara C, Sagan S. 2013. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 587:1693-702
146. ShaoK,Huang R, Li J, Han L, Ye L, et al. 2010. Angiopep-2modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J. Control. Release 147:118-26
147. ShaoK,Huang R, Li J, Han L, Ye L, et al. 2010. Angiopep-2modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J. Control. Release 147:118-26
148. Ke W, Shao K, Huang R, Han L, Liu Y, et al. 2009. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30:6976-85
149. Xin H, Sha X, Jiang X, Chen L, Law K, et al. 2012. The brain targeting mechanism of Angiopepconjugated poly(ethylene glycol)-co-poly(ϵ-caprolactone) nanoparticles. Biomaterials 33:1673-81
150. JinH, Kanthasamy A,Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. 2014. Mitochondriatargeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 1842:1282-94
151. Allen TM, Cullis PR. 2004. Drug delivery systems: entering the mainstream. Science 303:1818-22
152. Vela Ramirez JE, Roychoudhury R, Habte HH, Cho MW, Pohl NL, Narasimhan B. 2014. Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells. J. Biomater. Sci. 25:1387-406
153. Ross KA, LoydH,WuW,Huntimer L,WannemuehlerMJ, et al. 2014. Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles. J. Biomed. Mater. Res. A 102:4161-68
154. Haughney SL, Petersen LK, Schoofs AD, Ramer-Tait AE, King JD, et al. 2013. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. Acta Biomater. 9:8262-71
155. Petersen LK, Sackett CK, Narasimhan B. 2010. High-throughput analysis of protein stability in polyanhydride nanoparticles. Acta Biomater. 6:3873-81
156. Hua Z, Hou B. 2013. TLR signaling in B-cell development and activation. Cell. Mol. Immunol. 10:103-6
157. Plattner F, Yarovinsky F, Romero S, Didry D, Carlier MF, et al. 2008. Toxoplasma profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. Cell Host Microbe 3:77-87